Article Text
Abstract
Objective Ampullary neoplastic lesions can be resected by endoscopic papillectomy (EP) or transduodenal surgical ampullectomy (TSA) while pancreaticoduodenectomy is reserved for more advanced lesions. We present the largest retrospective comparative study analysing EP and TSA.
Design Of all patients in the database, lesions with prior interventions, benign histology advanced malignancy (T2 and more), patients with hereditary syndromes and those undergoing pancreatoduodenectomy were excluded. All remaining cases as well as a subgroup of them, after propensity-score matching (nearest-neighbour-method) based on age, gender, anthropometrics, comorbidities, size and histological subtype, were analysed. The median follow-up was 21 months (IQR 10–47) after the primary intervention. Primary outcomes were rates of complete resection (R0) and complications. Groups were compared by Fisher’s exact or χ2 test, Mann-Whitney-U-test and log-rank test for survival.
Results Of 1673 patients in the database, 1422 underwent EP and 251 TSA. Of them, 23.2% were excluded for missing or inconclusive data and 19.8% of patients for prior interventions or hereditary syndromes. Final histology showed in 24.2% of EP and 14.8% of TSA patients a histology other than adenoma or adenocarcinoma while advanced cancers were recorded in 10.9% of EP and 36.6% of TSA patients. Finally, 569 EP and 63 TSA were included in the overall analysis, with a higher rate of more advanced cases and higher R0 resection rates in the TSA groups (90.5% vs 73.1%; p<0.01), with additional ablation in the EP group in 14.4%. Severe adverse event rates were 3.2% (TSA) vs 1.9% (EP). Recurrence after histological R0 resection was 16% (EP) vs 3.2% (TSA; p=0.01), and additional therapy for R1 resection was applied in 67% of the 159 cases. Propensity-score-based matching identified 62 pairs of EP/TSA patients with comparable baseline patient and lesion characteristics. The initial R0-rate was 72.6% (EP) compared with 90.3% (TSA, p=0.02) with recurrences found in 8% (EP) vs 3.2% (TSA; p=0.07); reinterventions were more frequent in the EP group. Overall survival was comparable.
Conclusions The rate of patients with poor indications due to non-neoplastic disease or advanced cancer is still high for both EP and TSA; multiple retreatments were necessary for EP. Although EP can be considered an appropriate primary therapy for certain ampullary adenomas, case selection for both therapies (especially with regard to the best step-up approach) should be studied further.
- PANCREATICODUODENECTOMY
- ENDOSCOPIC PROCEDURES
- ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
- PANCREATIC CANCER
- PANCREATIC TUMOURS
Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.
Statistics from Altmetric.com
- PANCREATICODUODENECTOMY
- ENDOSCOPIC PROCEDURES
- ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
- PANCREATIC CANCER
- PANCREATIC TUMOURS
Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.
Footnotes
MH and CH are joint first authors.
SR and SG are joint senior authors.
X @KevinCSoaresMD, @steffen_sey, @StefanoCrippa6, @diogolibanio, @AnaDugic
MH and CH contributed equally.
SR and SG contributed equally.
Correction notice This article has been corrected since it published Online First. The equal contribution statement has been updated.
Collaborators Albrecht Hoffmeister (Division of Gastroenterology, Medical Department II, University of Leipzig Medical Center, Leipzig, Germany), Kien Vu Trung (Division of Gastroenterology, Medical Department II, University of Leipzig Medical Center, Leipzig, Germany), Jonas Rosendahl (Medical Department I, Martin-Luther University Halle-Wittenberg, Halle, Germany), Sebastian Krug (Medical Department I, Martin-Luther University Halle-Wittenberg, Halle, Germany; Medical Departmen IV—Gastroenterology, Hepatology, Infectious Diseases, Heidelberg University, Heidelberg, Germany), Lumir Kunovsky, Patrick Michl (Medical Department I, Martin-Luther University Halle-Wittenberg, Halle, Germany; Medical Departmen IV—Gastroenterology, Hepatology, Infectious Diseases, Heidelberg University, Heidelberg, Germany), Jens Werner (Department of General, Visceral and Transplantation Surgery, Ludwig Maximilian University Munich, Munich, Germany), Kestutis Strupas (Department of Surgery, Lithuanian University of Health Sciences, Santaros Klinikos, Kaunas, Lithuania), Lilian Schwarz (Department of Digestive Surgery, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France), Moritz Schiemer (Department of Medicine II, University of Freiburg Medical Center, Freiburg, Germany), Tullio Piardi (Department of Digestive Surgery, Centre Hospitalier Universitaire de Reims, Reims, France), Martin Brunel (Department of Digestive Surgery, Hôpital André Mignot, Versailles, France), Jean C. Vaillant(Department of Digestive and HBP Surgery, Groupe Hospitalier Pitié-Salpêtrière APHP, Médecine Sorbonne Université, Paris, France), Celine Lejeune (Medical Department, Hôpital de la Salpêtrière, APHP, Paris, France), Raffaele Brustia (Department of Digestive and Hepato-Pancreatic-Biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Inserm U955, Team 'Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers', France-Assistance Publique-Hôpitaux de Paris, Créteil, France), Rim Cherif (Department of Digestive and Hepato-Pancreatic-Biliary Surgery, DMU CARE, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; Inserm U955, Team 'Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers', France-Assistance Publique-Hôpitaux de Paris, Créteil, France), Paul-Noet Dumont (Department of Divbestive Surgery Hôpital de la Croix-Rousse, Lyon, France), Frederic Prat (Department of digestive, hepatobiliary and endocrine surgery, Cochin Hospital, APHP, and Université de Paris, Paris, France), J. Matthias Löhr (Division of Surgery, CLINTEC, Karolinska Institutet, Stockholm, Sweden)
Contributors MH and SG are guarantors and are responsible for overall content. MH and CH contributed equally and shared first authorship. SR and SG jointly supervised the project and shared senior authorship. MH designed the study, collected data, analysed data, interpreted data, wrote and submitted the manuscript. CH designed the study, collected data and revised the manuscript. EA-A designed the study, collected data and revised the manuscript. FA collected data and revised the manuscript. AG collected data and revised the manuscript. SR designed the study, collected data, interpreted data and revised the manuscript. SG designed the study, collected data, interpreted data and revised the manuscript. KSoares, GL, MAS, WRJ, TW, FCaillol, MG, YD, TH, WHP, AZ, GN, BN, UA, EH, AHalimi, AW, UW, RSaadeh, VM, SEvdW, MBruno, EPCR, PDeprez, ASauvanet, LBolm, TKeck, RSouche, J-MF, NM, GK, SSeyfried, MCP, AM, ZP, GB, SC, MF, SP, BY, IED, GOC, SSatoi, JMR, JG, AR, AAnderloni, CV, FCasciani, MDC, AO, RDS, AB, LM, RSalvia, PS, DW, YI, MDR, AL, DL, TKleemann, VS, MI, RA, JL, BS, DA, TC, LBarbier, ES, TJW, DH, AAlves, EK, NR, AD, SM, ST, KC, BM, BPM, MT, DB, RCM, EW, KSalzmann, MBruzzi, RML, PDavid, ASchmidt and CDP. AHoffmeister, KVT, JR, SK, PM, JW, KStrupas, LS, MS, TP, MBrunel, JCV, CL, RB, RC, P-ND, FP and JML collected data and revised the manuscript. All authors approved the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests MH: Honoraria from FUJIFILM for lectures and expert panel. Honoraria from Falk Foundation for lectures. MBruno: Boston Scientific: consultant (money to institution), support for industry and investigator-initiated studies. Cook Medical: consultant (money to institution), support for industry and investigator-initiated studies. Pentax Medical: consultant (money to institution), support for investigator-initiated studies. Mylan: lecturer, support for investigator-initiated studies. ChiRoStim: support for investigator-initiated studies.
MDC received a research grant Boston from Haemonetics,INC and he is co-PI of a Boston Scientific sponsored study
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.